{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "innate immunity",
      "interferons",
      "variants of concern"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35867811",
  "DateCompleted": {
    "Year": "2022",
    "Month": "07",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "08",
    "Day": "23"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "07",
        "Day": "22"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e2203760119",
      "10.1073/pnas.2203760119"
    ],
    "Journal": {
      "ISSN": "1091-6490",
      "JournalIssue": {
        "Volume": "119",
        "Issue": "32",
        "PubDate": {
          "Year": "2022",
          "Month": "Aug",
          "Day": "09"
        }
      },
      "Title": "Proceedings of the National Academy of Sciences of the United States of America",
      "ISOAbbreviation": "Proc Natl Acad Sci U S A"
    },
    "ArticleTitle": "Interferon resistance of emerging SARS-CoV-2 variants.",
    "Pagination": {
      "StartPage": "e2203760119",
      "MedlinePgn": "e2203760119"
    },
    "Abstract": {
      "AbstractText": [
        "The emergence of SARS-CoV-2 variants with enhanced transmissibility, pathogenesis, and resistance to vaccines presents urgent challenges for curbing the COVID-19 pandemic. While Spike mutations that enhance virus infectivity or neutralizing antibody evasion may drive the emergence of these novel variants, studies documenting a critical role for interferon responses in the early control of SARS-CoV-2 infection, combined with the presence of viral genes that limit these responses, suggest that interferons may also influence SARS-CoV-2 evolution. Here, we compared the potency of 17 different human interferons against multiple viral lineages sampled during the course of the global outbreak, including ancestral and five major variants of concern that include the B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), and B.1.1.529 (omicron) lineages. Our data reveal that relative to ancestral isolates, SARS-CoV-2 variants of concern exhibited increased interferon resistance, suggesting that evasion of innate immunity may be a significant, ongoing driving force for SARS-CoV-2 evolution. These findings have implications for the increased transmissibility and/or lethality of emerging variants and highlight the interferon subtypes that may be most successful in the treatment of early infections."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-1121-7603"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Guo",
        "ForeName": "Kejun",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Barrett",
        "ForeName": "Bradley S",
        "Initials": "BS"
      },
      {
        "Identifier": [
          "0000-0001-7385-5737"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Morrison",
        "ForeName": "James H",
        "Initials": "JH"
      },
      {
        "Identifier": [
          "0000-0003-2801-6234"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Mickens",
        "ForeName": "Kaylee L",
        "Initials": "KL"
      },
      {
        "Identifier": [
          "0000-0002-4160-8894"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Vladar",
        "ForeName": "Eszter K",
        "Initials": "EK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Rocky Mountain Laboratories, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840."
          }
        ],
        "LastName": "Hasenkrug",
        "ForeName": "Kim J",
        "Initials": "KJ"
      },
      {
        "Identifier": [
          "0000-0003-1598-5415"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Poeschla",
        "ForeName": "Eric M",
        "Initials": "EM"
      },
      {
        "Identifier": [
          "0000-0001-7792-2706"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045."
          }
        ],
        "LastName": "Santiago",
        "ForeName": "Mario L",
        "Initials": "ML"
      }
    ],
    "GrantList": [
      {
        "GrantID": "DP1 DA043915",
        "Acronym": "DA",
        "Agency": "NIDA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AI134220",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Research Support, N.I.H., Intramural",
      "Research Support, N.I.H., Extramural"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Proc Natl Acad Sci U S A",
    "NlmUniqueID": "7505876",
    "ISSNLinking": "0027-8424"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Neutralizing"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "9008-11-1",
      "NameOfSubstance": "Interferons"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "bioRxiv. 2021 Dec 10;:",
      "PMID": "33758840"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Neutralizing"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "immunology",
        "prevention & control",
        "transmission"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Interferons"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    }
  ],
  "CoiStatement": "The authors declare no competing interest."
}